Image of Gail H Cassell

Gail H Cassell, Ph.D.

Dr. Cassell is vice president for TB Drug Development at the Infectious Disease Research Institute in Seattle, Washington, professor emeritus and former chair, Department of Microbiology, University of Alabama at Birmingham, and former vice president for scientific affairs and distinguished Lilly research scholar for infectious diseases at Eli Lilly and Company in Indianapolis, Indiana. She founded the Forum on Drug Discovery, Development and Translation, which she continues to co-chair, at the Institute of Medicine. She has a distinguished record of national service with the National Academy of Sciences, National Institutes of Health, Centers for Disease Control, and several other national and international institutions.

Affiliations:

Division of Global Health Equity, Brigham and Women's Hospital

Dr. Cassell is a leader on efforts to address multidrug-resistant tuberculosis (MDRTB). She and Barry Bloom, former dean of Harvard School of Public Health, co-lead an Institute of Medicine project on drug supply chain issues related to MDRTB. She actively advises numerous government agencies, NGOs, and foundations on the scale-up of MDRTB diagnosis and treatment in endemic areas around the world, including in Russia. Dr. Cassell is advising the GHSM Sentinel Project on pediatric drug-resistant tuberculosis, a global partnership that aims to develop and deploy evidence-based strategies to prevent child deaths from drug-resistant tuberculosis.

Mycoplasma pulmonis V-1 surface protein variation: occurrence in vivo and association with lung lesions.
Authors: Authors: Talkington DF, Fallon MT, Watson HL, Thorp RK, Cassell GH.
Microb Pathog
View full abstract on Pubmed
Serum antibody does not account for differences in the severity of chronic respiratory disease caused by Mycoplasma pulmonis in LEW and F344 rats.
Authors: Authors: Simecka JW, Davis JK, Cassell GH.
Infect Immun
View full abstract on Pubmed
High-frequency variation in Mycoplasma pulmonis colony size.
Authors: Authors: Dybvig K, Simecka JW, Watson HL, Cassell GH.
J Bacteriol
View full abstract on Pubmed
Neonatal serologic response at term to the genital mycoplasmas.
Authors: Authors: Dinsmoor MJ, Ramamurthy RS, Cassell GH, Gibbs RS.
Pediatr Infect Dis J
View full abstract on Pubmed
Short-term exposure to nitrogen dioxide enhances susceptibility to murine respiratory mycoplasmosis and decreases intrapulmonary killing of Mycoplasma pulmonis.
Authors: Authors: Parker RF, Davis JK, Cassell GH, White H, Dziedzic D, Blalock DK, Thorp RB, Simecka JW.
Am Rev Respir Dis
View full abstract on Pubmed
Subunit structure of the variable V-1 antigen of Mycoplasma pulmonis.
Authors: Authors: Watson HL, Dybvig K, Blalock DK, Cassell GH.
Infect Immun
View full abstract on Pubmed
Induction of class II MHC antigen expression in macrophages by Mycoplasma species.
Authors: Authors: Stuart PM, Cassell GH, Woodward JG.
J Immunol
View full abstract on Pubmed
Ureaplasma urealyticum pneumonia: experimental production and demonstration of age-related susceptibility.
Authors: Authors: Rudd PT, Cassell GH, Waites KB, Davis JK, Duffy LB.
Infect Immun
View full abstract on Pubmed
Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.
Authors: Authors: Cassell GH, Waites KB, Pate MS, Canupp KC, Duffy LB.
Diagn Microbiol Infect Dis
View full abstract on Pubmed
Ureaplasmal pneumonia and sepsis associated with persistent pulmonary hypertension of the newborn.
Authors: Authors: Waites KB, Crouse DT, Philips JB, Canupp KC, Cassell GH.
Pediatrics
View full abstract on Pubmed